GeoVax Labs (NASDAQ:GOVX) Stock Rating Lowered by Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a research report issued on Saturday.

GOVX has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Wednesday, October 8th. D. Boral Capital reduced their price objective on shares of GeoVax Labs from $225.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, GeoVax Labs presently has a consensus rating of “Moderate Buy” and an average price target of $187.50.

GeoVax Labs Stock Performance

GOVX stock opened at $2.99 on Friday. The firm has a 50 day moving average price of $7.48 and a 200-day moving average price of $13.32. GeoVax Labs has a 52-week low of $2.61 and a 52-week high of $57.50. The firm has a market capitalization of $3.59 million, a price-to-earnings ratio of -0.08 and a beta of 3.67.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. As a group, sell-side analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in GeoVax Labs in the first quarter worth about $27,000. Hudson Bay Capital Management LP bought a new position in shares of GeoVax Labs in the 3rd quarter worth approximately $47,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs in the third quarter worth approximately $253,000. Finally, Sabby Management LLC bought a new stake in GeoVax Labs during the third quarter valued at approximately $313,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.